Navigation Links
Transcept Pharmaceuticals to Report Second Quarter 2009 Results
Date:8/6/2009

RICHMOND, Calif., Aug. 6 /PRNewswire-FirstCall/ -- Transcept Pharmaceuticals, Inc. (Nasdaq: TSPT), a specialty pharmaceutical company focused on the development and commercialization of proprietary products that address important therapeutic needs in the field of neuroscience, today announced it will report results for its quarter ended June 30, 2009 on Friday, August 14, 2009, prior to the opening of the market.

A conference call to review the results will begin at 8:30 a.m. ET (5:30 a.m. PT) on August 14, 2009 and will be hosted by Glenn A. Oclassen, President & Chief Executive Officer, and Thomas P. Soloway, Senior Vice President & Chief Financial Officer.

To participate in the conference call, please dial 877-397-0284 (USA) or 719-325-4890 (International). In addition, a dial-up replay of the conference call will be available from August 14, 2009 through August 26, 2009. The replay telephone number is 888-203-1112 (USA) or 719-457-0820 (International), Replay Passcode: 2582954.

A live webcast of the call will also be available from the Investors section on the corporate web site at www.transcept.com. A webcast replay can be accessed on the corporate web site beginning August 14, 2009 at the same time as the conference call and will remain on the site through August 28, 2009.

About Intermezzo(R)

Intermezzo(R) (zolpidem tartrate sublingual tablet), the lead product candidate at Transcept, has the potential to be the first prescription sleep aid specifically approved for use in the middle of the night at the time a patient awakens and has difficulty returning to sleep. Intermezzo(R) is a sublingual low dose formulation of zolpidem, the active agent most commonly prescribed in the Un
'/>"/>

SOURCE Transcept Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Transcept Pharmaceuticals to Hold Conference Call on Agreement with Purdue Pharmaceutical Products L.P. to Commercialize Intermezzo(R) in the United States
2. Transcept Pharmaceuticals to Present at BMO Capital Markets Healthcare Conference on August 5, 2009
3. Transcept Pharmaceuticals Announces Expected FDA Extension of Regulatory Review Period for Intermezzo(R)
4. Transcept Pharmaceuticals to Present at Needham Life Sciences Conference on June 10, 2009
5. Transcept Pharmaceuticals Presents Data from Studies of Two Product Candidates at Annual Meeting of the American Psychiatric Association
6. Transcept Pharmaceuticals Reports First Quarter 2009 Financial Results
7. Transcept Pharmaceuticals Appoints Joseph T. Kennedy as General Counsel
8. Transcept Pharmaceuticals Reports Fourth Quarter and Year End 2008 Financial Results
9. Transcept Pharmaceuticals to Report Fourth Quarter 2008 Results
10. Transcept Pharmaceuticals to Present at Two Upcoming Conferences
11. Transcept Pharmaceuticals, Inc. Completes Merger with Novacea, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/1/2014)... Summer is here, and with it comes the season ... they can be a pain for dogs. Animal Emergency & ... customers get rid of ticks and prevent them completely. , ... summer, which is why they are so active during this ... areas and carry a number of diseases, including lyme disease, ...
(Date:8/1/2014)... August 01, 2014 As AndroGel lawsuits ... country, Ronald E. Johnson, Jr. has been appointed as ... and other testosterone medications. Since the Fall of 2013, ... have worked diligently to investigate and prosecute the claims ... and blood clots as a result of taking testosterone. ...
(Date:8/1/2014)... benefits of a cancer diagnosis may improve health outcomes ... conducted by a researcher at the University of Houston ... writing intervention is the writing instruction. Otherwise, writing is ... a journal can be therapeutic, but oftentimes we don,t ... or not," said Qian Lu, assistant professor and director ...
(Date:8/1/2014)... 01, 2014 Growing prevalence of ... healthcare reforms are boosting healthcare market growth, although ... discounts and increasing generic consumption is a major ... million in 2013, having grown at a Compound ... The implementation of the Health Transformation Program (Saglikta ...
(Date:8/1/2014)... Hawley, PA (PRWEB) August 01, 2014 Hot ... in the destination spa category of the World’s Best ... kicks off a month-long celebration of National Relaxation Day (technically ... together a series of MAJOR experts to help guests celebrate ... how important it is for health and wellness to carve ...
Breaking Medicine News(10 mins):Health News:Tis the Season for Tick Prevention 2Health News:Ron Johnson Named Co-Lead Counsel in Lawsuits for Men Injured by AndroGel and Testosterone 2Health News:Expressive writing may help breast cancer survivors 2Health News:Expressive writing may help breast cancer survivors 3Health News:Turkey Pharmaceutical and Medical Device Market Worth $21.5B & $3.3B by 2020 Respectively, Says a Report Available at MarketOptimizer.org 2Health News:Turkey Pharmaceutical and Medical Device Market Worth $21.5B & $3.3B by 2020 Respectively, Says a Report Available at MarketOptimizer.org 3Health News:Turkey Pharmaceutical and Medical Device Market Worth $21.5B & $3.3B by 2020 Respectively, Says a Report Available at MarketOptimizer.org 4Health News:The Lodge at Woodloch Kicks Off National Relaxation Day with a Month Long Celebration 2Health News:The Lodge at Woodloch Kicks Off National Relaxation Day with a Month Long Celebration 3Health News:The Lodge at Woodloch Kicks Off National Relaxation Day with a Month Long Celebration 4
... traffic pollution may increase respiratory problems and reduce lung ... studied the effects of road and traffic density on ... town of Ciudad Juarez in Mexico. , Our results ... at home or at school, can lead to chronic ...
... 13 The owners of five,separate Miami-based health ... Assistant Attorney General Alice S. Fisher of the ... the Southern District of,Florida announced today. Collectively, the ... $28.6 million worth of unnecessary durable,medical equipment (DME) ...
... Inc. (Nasdaq: ISIS ) announced today that ... orphan drug status to ISIS 333611 for,the treatment ... (ALS),commonly referred to as Lou Gehrig,s disease. ALS ... of muscle control that can,lead to death. ISIS ...
... part of NDA submission in 2009, SYDNEY, Australia, ... of a second Phase III clinical trial for its,lead ... placebo controlled, double blind safety extension trial is,designed to ... the,Company,s submission of a New Drug Application (NDA) to ...
... 13 This year, pack nutrients,into your holiday ... sponsored by Dairy Council of California.,Instead of ... serve lightened-up holiday classics like Candy Cane Cocoa, ... and the bone-building benefits,of calcium, a much-needed nutrient ...
... Mass. and NEW YORK, Dec. 13 Boston,Scientific ... Partners, a leading,private equity firm, today jointly announced ... will acquire from Boston Scientific its Fluid,Management and ... The,transaction is expected to close in the first ...
Cached Medicine News:Health News:Heavy traffic makes breathing a burden in children 2Health News:Medicare Fraud Strike Force Cases Result in Long Prison Terms for Five Health Care Company Owners 2Health News:Medicare Fraud Strike Force Cases Result in Long Prison Terms for Five Health Care Company Owners 3Health News:Medicare Fraud Strike Force Cases Result in Long Prison Terms for Five Health Care Company Owners 4Health News:Isis Announces ISIS 333611 Granted Orphan Drug Status for Treatment of ALS 2Health News:Isis Announces ISIS 333611 Granted Orphan Drug Status for Treatment of ALS 3Health News:QRxPharma Initiates Second Phase III Clinical Trial for its 'Dual Opioid' Pain Therapy 2Health News:Seasonal Sippers Supply Bone-Building Benefits 2Health News:Seasonal Sippers Supply Bone-Building Benefits 3Health News:Boston Scientific Agrees To Sell Fluid Management and Venous Access Businesses to Avista Capital Partners for $425 Million 2Health News:Boston Scientific Agrees To Sell Fluid Management and Venous Access Businesses to Avista Capital Partners for $425 Million 3Health News:Boston Scientific Agrees To Sell Fluid Management and Venous Access Businesses to Avista Capital Partners for $425 Million 4Health News:Boston Scientific Agrees To Sell Fluid Management and Venous Access Businesses to Avista Capital Partners for $425 Million 5
(Date:7/31/2014)... 31, 2014 STAAR Surgical Company (NASDAQ: ... of implantable lenses and delivery systems for the eye ... 4, 2014 of $20.0 million, a 10% increase over ... On a constant currency basis, revenues grew 11% during ... quarter of 2013.  The effect of foreign currency exchange ...
(Date:7/31/2014)... -- ResMed Inc. (NYSE: RMD ) today announced results ... June 30, 2014.  Revenue for the quarter was $415.2 million, ... 1 percent decrease on a constant currency basis). Net income ... the quarter ended June 30, 2013. Diluted earnings per share ... compared to the quarter ended June 30, 2013.  ...
(Date:7/31/2014)... Xencor Inc. (NASDAQ: XNCR ), a ... the treatment of autoimmune diseases, asthma and allergic ... the second quarter ended June 30, 2014 and provided ... "In the second quarter, we presented preclinical data ... (ATS) demonstrating three novel mechanisms of action of ...
Breaking Medicine Technology:STAAR Surgical Reports 10% Second Quarter Revenue Growth 2STAAR Surgical Reports 10% Second Quarter Revenue Growth 3STAAR Surgical Reports 10% Second Quarter Revenue Growth 4STAAR Surgical Reports 10% Second Quarter Revenue Growth 5STAAR Surgical Reports 10% Second Quarter Revenue Growth 6STAAR Surgical Reports 10% Second Quarter Revenue Growth 7STAAR Surgical Reports 10% Second Quarter Revenue Growth 8STAAR Surgical Reports 10% Second Quarter Revenue Growth 9STAAR Surgical Reports 10% Second Quarter Revenue Growth 10STAAR Surgical Reports 10% Second Quarter Revenue Growth 11STAAR Surgical Reports 10% Second Quarter Revenue Growth 12STAAR Surgical Reports 10% Second Quarter Revenue Growth 13STAAR Surgical Reports 10% Second Quarter Revenue Growth 14STAAR Surgical Reports 10% Second Quarter Revenue Growth 15STAAR Surgical Reports 10% Second Quarter Revenue Growth 16STAAR Surgical Reports 10% Second Quarter Revenue Growth 17STAAR Surgical Reports 10% Second Quarter Revenue Growth 18STAAR Surgical Reports 10% Second Quarter Revenue Growth 19STAAR Surgical Reports 10% Second Quarter Revenue Growth 20STAAR Surgical Reports 10% Second Quarter Revenue Growth 21STAAR Surgical Reports 10% Second Quarter Revenue Growth 22STAAR Surgical Reports 10% Second Quarter Revenue Growth 23STAAR Surgical Reports 10% Second Quarter Revenue Growth 24STAAR Surgical Reports 10% Second Quarter Revenue Growth 25STAAR Surgical Reports 10% Second Quarter Revenue Growth 26STAAR Surgical Reports 10% Second Quarter Revenue Growth 27STAAR Surgical Reports 10% Second Quarter Revenue Growth 28STAAR Surgical Reports 10% Second Quarter Revenue Growth 29STAAR Surgical Reports 10% Second Quarter Revenue Growth 30STAAR Surgical Reports 10% Second Quarter Revenue Growth 31RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 2RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 3RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 4RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 5RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 6
No. 1. 30 mm conventional blades. Thin well-rounded tips....
Aspirating adjustable lid speculum is ideal for cataract and laser refractive procedures....
Open 15 mm blades with lifting wings manipulation of I/A cannulas, knives, instrumentation, etc. Screwlocking mechanism. Dull finish....
Solid 8 mm blades. Dull finish. Most popular size or model....
Medicine Products: